Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 8,367 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: serum sample Clear all
Completed Phase 2Phase 3 Interventional

Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome

NCT00111956
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Etanercept, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 16, 2026, 5:55 AM EDT
Completed Not applicable Interventional Results available

Skin Care for Cancer Patients: A Product Satisfaction Survey

NCT00871429
View directory record Official record
Conditions
Skin Toxicity
Interventions
Lindi skin care products
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 16, 2026, 5:55 AM EDT
Completed Phase 1 Interventional

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

NCT00458731
View directory record Official record
Conditions
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Progressive Hairy Cell Leukemia, Initial Treatment, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Childhood Anaplastic Large Cell Lymphoma, Stage IV Childhood Hodgkin Lymphoma, Stage IV Childhood Large Cell Lymphoma, Stage IV Childhood Lymphoblastic Lymphoma, Stage IV Childhood Small Noncleaved Cell Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
bevacizumab, cediranib maleate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced Oct 16, 2026, 5:55 AM EDT
Completed Early Phase 1 Interventional

Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer

NCT03162731
View directory record Official record
Conditions
Larynx, Lip, Oral Cavity and Pharynx
Interventions
Nivolumab, Ipilimumab, Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy
Biological · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 16, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Results available

Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

NCT00782275
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
bevacizumab, temsirolimus
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 16, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer

NCT00192075
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Gemcitabine, avastin, 5FU/folinic acid, oxaliplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
15
States / cities
Tucson, Arizona • Beverly Hills, California • Palm Springs, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Oct 16, 2026, 5:55 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

NCT04356729
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma, Unresectable Stage IV Cutaneous Melanoma
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
F. Stephen Hodi, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 16, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

Stem Cell Transplantation for Sickle Cell Anemia

NCT01877837
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, Fludarabine, Melphalan, Stem Cells
Drug · Procedure
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
2 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 16, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Results available

Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma

NCT00516295
View directory record Official record
Conditions
Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Interventions
topotecan hydrochloride, vincristine sulfate, cyclophosphamide, bevacizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 29 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 2, 2014 · Synced Oct 16, 2026, 5:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

NCT03369223
View directory record Official record
Conditions
Advanced Cancer
Interventions
BMS-986249, Nivolumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
19
States / cities
Aurora, Colorado • Denver, Colorado • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 16, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Results available

Study of Ramucirumab in Ovarian Cancer

NCT00721162
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
Ramucirumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
11
States / cities
Hollywood, Florida • Orlando, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 16, 2026, 5:55 AM EDT
Completed Phase 4 Interventional Results available

Rheumatoid Arthritis Memory B Cells and Abatacept

NCT03652961
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, DMARDs
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 16, 2026, 5:55 AM EDT
Active, not recruiting Not applicable Interventional

Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy

NCT02698254
View directory record Official record
Conditions
Recurrent Brain Neoplasm
Interventions
Bevacizumab, Quality-of-Life Assessment, Radiation Therapy
Biological · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 16, 2026, 5:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intraarticular Antibiotic in TKA

NCT04297631
View directory record Official record
Conditions
Antibotics in Cementless Knees
Interventions
Tobramycin Powder, Vancomyscin
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 16, 2026, 5:55 AM EDT
Enrolling by invitation Phase 4 Interventional

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

NCT05185505
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 16, 2026, 5:55 AM EDT
Completed Phase 1Phase 2 Interventional

Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes

NCT00093366
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
etanercept, arsenic trioxide
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 16, 2026, 5:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Oral OKT3 for the Treatment of Active Ulcerative Colitis

NCT01287195
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Oral OKT3, Omeprazole
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Oct 16, 2026, 5:55 AM EDT
Terminated Early Phase 1 Interventional

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

NCT01730157
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Liver Metastases, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Stage IV Intraocular Melanoma
Interventions
ipilimumab, yttrium Y 90 glass microspheres, laboratory biomarker analysis
Biological · Radiation · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 16, 2026, 5:55 AM EDT
Completed Phase 1 Interventional

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

NCT04495257
View directory record Official record
Conditions
Advanced Melanoma, Renal Cell Carcinoma
Interventions
Nivolumab, Ipilimumab, APX005M
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 16, 2026, 5:55 AM EDT
Completed No phase listed Observational

Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

NCT03399981
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy
Interventions
Tysabri
Biological
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
80,327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 16, 2026, 5:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

COMIDAS Comparing Original Mexican Diets and Standard US Diets

NCT01369173
View directory record Official record
Conditions
Healthy
Interventions
Mexican or American foods
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 16, 2026, 5:55 AM EDT
Completed Phase 2 Interventional

Study of Cimzia for the Treatment of Ulcerative Colitis

NCT01090154
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Cimzia
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 16, 2026, 5:55 AM EDT
Completed Phase 4 Interventional Results available

Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis

NCT01753856
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Denosumab, Demeclocycline, Tetracycline, Calcium Supplement, Vitamin D
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 89 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Lakewood, Colorado • Gainesville, Georgia • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 16, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma

NCT00547534
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
bortezomib, bendamustine, rituximab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Omaha, Nebraska • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Oct 16, 2026, 5:55 AM EDT